ES-481 is under clinical development by ES Therapeutics and currently in Phase II for Epilepsy. According to GlobalData, Phase II drugs for Epilepsy have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ES-481’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ES-481 overview
ES-481 (CERC-611) is under development for the treatment of essential tremor and drug resistant epilepsy. The drug candidate is administered orally. It acts by targeting transmembrane AMPA receptor regulatory proteins (TARP)-gamma 8-dependent AMPA receptor. The drug candidate is a new chemical entity.
It was under development for the treatment of glioma, partial-onset seizures in epilepsy, neuropathic pain and depression.
ES Therapeutics overview
ES Therapeutics is engaged in providing healthcare services. It provides drug development, diagnostic services, clicinal analysis, therapeutics services and other services. ES Therapeutics is headquartered in Albany, New York, the US
For a complete picture of ES-481’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
